by Kai Herdin | Feb 5, 2026 | News
A new abstract, presented at the American Stroke Association’s Conference, explores how NAD and NADP, critical molecules for cellular energy and repair, change in the early days after stroke and what that might mean for recovery. Preliminary findings (n=18) showed: •...
by Kai Herdin | Jan 4, 2026 | News
A study in Cell Reports Medicine shows significantly lower NAD+ levels in the brains of Alzheimer’s patients, especially in the parietal and occipital regions. The findings highlight a strong correlation between NAD+ depletion and mitochondrial dysfunction,...
by Kai Herdin | Nov 26, 2025 | News
A newly published study reveals that NAD⁺ can restore memory in Alzheimer’s disease models by correcting RNA splicing errors. This groundbreaking international research demonstrates how boosting this essential metabolic molecule improves memory and neuronal function...
by Kai Herdin | Sep 12, 2025 | News
NADMED has been selected to join the prestigious AMPlify program, a U.S. market entry initiative jointly organized by Mayo Clinic and Business Finland. The program combines world-class clinical expertise, valuable market knowledge, and extensive networks to support...
by Kai Herdin | Mar 4, 2025 | News
Affinity Biomarker Labs, based in London, UK, is the latest partner to join the NADMED network, offering NAD+ and NADH testing upon request. Established in 2017 at Imperial College London’s White City Campus, Affinity Biomarker Labs was founded by a team of clinical...